Sarepta Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The following table contains information regarding our purchases of our common stock during the quarter.
| ISSUER PURCHASES OF EQUITY SECURITIES | ||||
|---|---|---|---|---|
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly announced Plans or Programs (a) | Approximate Dollar Value (in thousands) of Shares that May Yet Be Purchased Under the Plans or Programs (a) |
| April 1-30, 2025 | — | $— | — | $500,000 |
| May 1-31, 2025 | 650,876 | 38.41 | 650,876 | 475,000 |
| June 1-30, 2025 | — | — | — | 475,000 |
| Total | 650,876 | $38.41 | 650,876 | |
(a) All Common Stock repurchases during the quarter were made under the November 2024 authorization from our Board of Directors to purchase up to $500.0 million of our outstanding Common Stock. See Note 10, Equityto our unaudited condensed consolidated financial statements included in this Quarterly Report for additional information.
Repurchases under the authorized stock repurchase program may be made using a variety of methods, which may include, but are not limited to, open market purchases, privately negotiated transactions, accelerated share repurchase agreements or purchases pursuant to a Rule 10b5-1 plan under the Securities Exchange Act of 1934, as amended. The authorization from our Board expires in May 2026 and may be suspended, delayed or discontinued at any time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.